Cargando...
Efficacy of eplerenone in the management of mineralocorticoid excess in men with metastatic castration resistant prostate cancer treated with abiraterone without prednisone
Prednisone is typically co-administered with abiraterone in treatment of castrate resistant prostate cancer to prevent toxicities of secondary mineralocorticoid excess. However, many patients do not desire or cannot tolerate chronic glucocorticoid therapy. In this retrospective study, we report that...
Gardado en:
| Publicado en: | Clin Genitourin Cancer |
|---|---|
| Main Authors: | , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2017
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5501307/ https://ncbi.nlm.nih.gov/pubmed/28131750 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2016.12.008 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|